Docoh
Loading...

GMTX Gemini Therapeutics

News

From Benzinga Pro
Gemini Therapeutics Q3 EPS $(0.43)
15 Nov 21
Earnings, News
Gemini Therapeutics (NASDAQ:GMTX) reported quarterly losses of $(0.43) per share.
Goldman Sachs Maintains Buy on Gemini Therapeutics, Lowers Price Target to $18
6 Oct 21
News, Price Target, Analyst Ratings
Goldman Sachs analyst Graig Suvannavejh maintains Gemini Therapeutics (NASDAQ:GMTX) with a Buy and lowers the price target from $20 to $18.
Gemini Axes Chief Scientific Officer, 20% Of Staff To Focus On Geographic Atrophy Candidate
5 Oct 21
Biotech, News, Penny Stocks, Health Care, General
Gemini Therapeutics Inc (NASDAQ: GMTX) announced a corporate restructuring, including several executive officer transitions, prioritizing assets, and focusing on GEM103's pivotal trial in geographic atrophy (GA).
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
Gemini Therapeutics Announces Presentation Of Preclinical Data At 13th International Conference On Complement Therapeutics
10 Sep 21
News, FDA
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation
12 Health Care Stocks Moving In Thursday's After-Market Session
9 Sep 21
Movers
Gainers
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
9 Sep 21
News
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D.,

Press releases

From Benzinga Pro
Gemini Therapeutics Announces Poster Presentation at AAO 2021
12 Nov 21
Press Releases
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi,
Gemini Therapeutics to Participate in Upcoming Investor Conferences
11 Nov 21
Press Releases
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg,
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
19 Oct 21
Press Releases
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced Chief Medical
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
14 Oct 21
Press Releases
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
5 Oct 21
Press Releases
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced a corporate
Lightstone Ventures Raises $375 Million Fund
14 Sep 21
Press Releases
MENLO PARK, Calif. and BOSTON, Sept. 14, 2021 /PRNewswire/ -- Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
10 Sep 21
Press Releases
- Studies show mechanism of action and biodistribution of GEM103 and support continued development as a potential treatment for AMD Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company